Biogen gets the first in 8 years FDA approval for a multiple ...
289071
Today was a day of good news for multiple sclerosis patients: FDA granted approval to a new anti-multiple sclerosis drug Antegren developed by Biogen Idec Inc.
68266
Gilead gets marketing approval for one of its drug candidates.
289662
Biogen Idec Inc. BIIB.O on Monday  reported a quarterly profit on sales of its multiple sclerosis  and cancer drugs versus a year-ago loss, but said costs will  rise in 2005, trimming earnings growth and weighing on shares.
477606
Becton, Dickinson gets FDA approval of its latest (rapid) superbug detection test.
132487
For those that missed it last night, Biogen Idec (BIIB:Nasdaq - news - research) and Elan Pharmaceuticals (ELN:NYSE ADR - news - research) received FDA approval for their new multiple sclerosis drug, now called Tysabri (formerly known as Antegren.
293341
Biogen Idec Inc.&#39;s Tysabri drug for multiple sclerosis may reach patients as soon as next week, and doctors said they plan to prescribe it first to patients who are no longer being helped by older medicines.
427900
BOSTON  Â Biogen Idec said on Wednesday its fourth-quarter profit rose 84 percent, topping expectations, driven by increased sales of its multiple sclerosis drugs Avonex and Tysabri.
222069
The first generic version of Lexapro, one of the most widely prescribed antidepressants, with more than $2 billion in sales last year, received federal approval Monday.
560148
The Food and Drug Administration approved Clolar, Genzyme Corp.&#39;s new drug for patients under 21 with acute lymphocytic leukemia.
59092
The FDA, which has been under criticism for its lengthy approval process, this week approved two new drugs for multiple sclerosis and cancer treatment.
147168
The approval of a new drug is a long-term opportunity.
766094
DUBLIN/NEW YORK  - Patients taking an experimental  multiple sclerosis drug developed by Biogen Idec Inc. BIIB.O  and Elan Corp. ELN.I experienced far fewer relapses in a  clinical trial, data that analysts say could give the drug a  dominant market position.
205700
Elan shares jumped this morning after it said that US regulators had approved it new once-a-month multiple sclerosis drug. Tysabri, developed by Elan and Biogen and formerly called Antegren, is the first kind
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
623395
Biogen Idec Inc. of Cambridge said it is in final discussions with the Food and Drug Administration about its new multiple sclerosis drug Antegren, and expects the drug to be approved by the end of the month.
519946
The Food and Drug Administration (FDA) today announced the issuance of a final rule on current good tissue practice (GTP), the last of three rules to be finalized as part of the Agency&#39;s overall plan to make human cells and tissues even safer.
737440
An unsurprising response from the FDA.